DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20200801

Borderline ovarian tumour of mixed seromucinous histology and bilateral presentation: a case report and review of literature

Monika Anant, Sutapan Samanta, Ruchi Sinha

Abstract


This article reports the case of a 40 year old woman who presented to the gynaecologic outpatient clinic with pain lower abdomen and an abdominopelvic lump. Clinical assessment, biochemical and radiological investigations revealed bilateral complex ovarian masses. Surgical exploration and histology of ovarian masses confirmed a rare bilateral borderline seromucinous cystadenoma. The purpose of this paper is to highlight the importance of thorough examination of women with symptoms of ovarian tumour which can be vague and to emphasize the necessity of a good collaboration between various medical specialties (primary physician/gynaecologist, oncosurgeon, radiologist and histopathologist) for correct diagnosis, optimum care and best outcome. This article also provides overview of the pathology and biology of borderline ovarian tumours, diagnosis, principles of surgical management and to appreciate the value of follow up.


Keywords


Borderline ovarian tumor, Bilateral, Seromucinous, Surgical staging

Full Text:

PDF

References


Sutton GP. Ovarian tumors of low malignant potential. In: Rubin SC, Sutton GP, eds. Ovarian Cancer. 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2001: 399-417.

Skírnisdóttir I, Garmo H, Wilander E, Holmberg L. Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. Int J Cancer. 2008 Oct 15;123(8):1897-901.

Sherman ME, Berman J, Birrer MJ, Cho KR, Ellenson LH, Gorstein F, Seidman JD. Current challenges and opportunities for research on borderline ovarian tumors. Human Pathol. 2004 Aug 1;35(8):961-70.

Bagade P, Edmondson R, Nayar A. Management of borderline ovarian tumours. Obstetric Gynaecol. 2012 Apr 1;14(2):115-20.

Taylor HC. Malignant and semimalignant tumors of the ovary. Surg Gynecol Obstet. 1929;48:204-30.

Kottmeier HL. Classification and staging of malignant tumors in the female pelvis. Int J Gynecol Obstet. 1971;9:172.

Serov, S. F, Scully, Robert Edward, Sobin, Leslie H and World Health Organization‎. Histological typing of ovarian tumours / S. F. Serov, R. E. Scully, in collaboration with L. H. Sobin and pathologists in ten countries. World Health Organization; ‎1973. Available in: https://apps.who.int/iris/handle/10665/41529.

Scully RE, R.L., Histologic typing of ovarian tumors. In: World Health Organaization International Histological Classification of Tumors. 2nd ed Springer-Verlag. Berlin, Heidelberg, 1. 1999.

Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for epithelial borderline ovarian tumors: results of a Swedish case-control study. Gynecol Oncol. 2001 Dec 1;83(3):575-85.

Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA‐associated ovarian carcinoma. Cancer: Interdisciplinary Int J Am Cancer Soci. 2003 May 1;97(9):2187-95.

Kobel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmera C, et al. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Medi. 2008 Dec 1;5(12):1749-61.

Sood, A.K., Matsuo, K., Gershenson, D.M., Management of early-stage ovarian cancer. In: Bristow, R.E., Karlan, B.Y. eds. Surgery for Ovarian Cancer: Principles and Practice. Chapter 3, 2nd ed. Vol 3. New York: Informa Healthcare, 2010:37-60.

Diaz-Padilla I, Malpica AL, Minig L, Chiva LM, Gershenson DM, Gonzalez-Martin A. Ovarian low-grade serous carcinoma: a comprehensive update. Gynecol Oncol. 2012 Aug 1;126(2):279-85.

Abascal-Saiz A, Sotillo-Mallo L, De Santiago J, Zapardiel I. Management of borderline ovarian tumours: a comprehensive review of the literature. Ecancer Med Sci. 2014;8.

Hart WR, Norris HJ. Borderline and malignant mucinous tumors of the ovary. Histologic criteria and clinical behavior. Cancer. 1973 May;31(5):1031-45.

Lalwani N, Shanbhogue AK, Vikram R, Nagar A, Jagirdar J, Prasad SR. Current update on borderline ovarian neoplasms. Am J Roentgenol. 2010 Feb;194(2):330-6.

Tropé CG, Kaern J, Davidson B. Borderline ovarian tumours. Best Pract Res Clini Obst Gynaecol. 2012 Jun 1;26(3):325-36.

Pickel H, Tamussino K. History of gynecological pathology: XIV. Hermann johannes pfannenstiel. Int J Gynecol Pathol. 2003 Jul 1;22(3):310-4.

Gotlieb WH, Soriano D, Achiron R, Zalel Y, Davidson B, Kopolovic J, Novikov I, Ben-Baruch G. CA 125 measurement and ultrasonography in borderline tumors of the ovary. Am J Obst Gynecol. 2000 Sep 1;183(3):541-6.

Zanetta G, Vergani P, Lissoni A. Color Doppler ultrasound in the preoperative assessment of adnexal masses. Acta Obstetr Gynecol Scandin. 1994 Sep;73(8):637-41.

Bent CL, Sahdev A, Rockall AG, Singh N, Sohaib SA, Reznek RH. MRI appearances of borderline ovarian tumours. Clini Radiol. 2009 Apr 1;64(4):430-8.

Patrono MG, Minig L, Diaz-Padilla I, Romero N, Moreno JF, Garcia-Donas J. Borderline tumours of the ovary, current controversies regarding their diagnosis and treatment. Ecancer Med Sci. 2013;7:379.

Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary. Semin Surg Oncol. 2000;19(1):69-75.

Schutter EM, Davelaar EM, van Kamp GJ, Verstraeten RA, Kenemans P, Verheijen RH. The differential diagnostic potential of a panel of tumor markers (CA 125, CA 15-3, and CA 72-4 antigens) in patients with a pelvic mass. Am J Obst Gynecol. 2002 Aug 1;187(2):385-92.

Engelen MJ, de Bruijn HW, Hollema H, Klaske A, Willemse PH, Aalders JG, et al. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors. Gynecol Oncol. 2000 Jul 1;78(1):16-20.

Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre‐operative diagnosis of pelvic masses. BJOG: Int J Obst Gynaecol. 1996 Aug;103(8):826-31.

Van Holsbeke C, Van Calster B, Bourne T, Ajossa S, Testa AC, Guerriero S, et al. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clinical Cancer Research. 2012 Feb 1;18(3):815-25.

Naik R, Cross P, Lopes A, Godfrey K, Hatem MH. “True” versus “apparent” stage I epithelial ovarian cancer: value of frozen section analysis. Int J Gynecol Cancer. 2006 Jan 1;16(Suppl 1):41-6.

Rao GG, Skinner E, Gehrig PA, Duska LR, Coleman RL, Schorge JO. Surgical staging of ovarian low malignant potential tumors. Obst Gynecol. 2004 Aug 1;104(2):261-6.

Camatte S, Morice P, Thoury A, Fourchotte V, Pautier P, Lhomme C, et al. Impact of surgical staging in patients with macroscopic “stage I” ovarian borderline tumours: analysis of a continuous series of 101 cases. Eur J Cancer. 2004 Aug 1;40(12):1842-9.

Trillsch F, Mahner S, Ruetzel JD, Harter P, Ewald-Riegler N, Jaenicke F, et al. Clinical management of borderline ovarian tumors. Expert Rev Antican Ther. 2010 Jul 1;10(7):1115-24.

Morice P, Camatte S, Rey A, Atallah D, Lhomme C, Pautier P, et al. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary. Ann Oncol. 2003 Apr 1;14(4):592-8.

Seidman JD, Kurman RJ. Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators. Human Pathol. 2000 May 1;31(5):539-57.

Cadron I, Leunen K, Van Gorp T, Amant F, Neven P, Vergote I. Management of borderline ovarian neoplasms. J Clini Oncol. 2007 Jul 10;25(20):2928-37.

Du Bois A, Ewald-Riegler N, Du Bois O, Harter P. Borderline-tumoren des Ovars–eine systematische Übersicht. Geburtshilfe und Frauenheilkunde. 2009 Sep;69(09):807-33.

Morice P. Borderline tumours of the ovary and fertility. Eur J cancer. 2006 Jan 1;42(2):149-58.

Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E. Laparoscopic management of borderline ovarian tumors: results of a French multicenter study. Ann Oncol. 2005 Mar 1;16(3):403-10.

Ramirez PT, Slomovitz BM, Soliman PT, Coleman RL, Levenback C. Total laparoscopic radical hysterectomy and lymphadenectomy: the MD Anderson Cancer Center experience. Gynecol Oncol. 2006 Aug 1;102(2):252-5.

Barnhill DR, Kurman RJ, Brady MF, Omura GA, Yordan E, Given FT, et al. Preliminary analysis of the behavior of stage I ovarian serous tumors of low malignant potential: a Gynecologic Oncology Group study. J Clini Oncol. 1995 Nov;13(11):2752-6.

Zanetta G, Rota S, Lissoni A, Meni A, Brancatelli GT, Buda A. Ultrasound, physical examination, and CA 125 measurement for the detection of recurrence after conservative surgery for early borderline ovarian tumors. Gynecol Oncol. 2001 Apr 1;81(1):63-6.

Centers for Disease Control and Prevention (CDC). US Medical Eligibility Criteria for contraceptive use MMW RRecommRep 59(RR-4); 2010:1-86.

Silva EG, Gershenson DM, Malpica A, Deavers M. The recurrence and the overall survival rates of ovarian serous borderline neoplasms with noninvasive implants is time dependent. The Am J Surg Pathol. 2006 Nov 1;30(11):1367-71.